Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Twelve‐month Outcomes After Coronary Stenting With the Genous™ Bio‐Engineered R Stent™ in Diabetic Patients from the e‐HEALING Registry

Twelve‐month Outcomes After Coronary Stenting With the Genous™ Bio‐Engineered R Stent™ in... Objectives: We compared 12‐month outcomes, regarding ischemic events, repeat intervention, and ST, between diabetic and nondiabetic patients treated with the Genous™ EPC capturing R stent™ during routine nonurgent percutaneous coronary intervention (PCI) using data from the multicenter, prospective worldwide e‐HEALING registry. Background: Diabetic patients have an increased risk for restenosis and stent thrombosis (ST). Methods: In the 4,996 patient e‐HEALING registry, 273 were insulin requiring diabetics (IRD), 963 were non‐IRD (NIRD), and 3,703 were nondiabetics. The 12‐month primary outcome was target vessel failure (TVF), defined as target vessel–related cardiac death or myocardial infarction (MI) and target vessel revascularization. Secondary outcomes were the composite of cardiac death, MI or target lesion revascularization (TLR), and individual outcomes including ST. Cumulative event rates were estimated with the Kaplan–Meier method and compared with a log‐rank test. Results: TVF rates were respectively 13.4% in IRD, 9.0% in NIRD, and 7.9% in nondiabetics (P < 0.01). This was mainly driven by a higher mortality hazard in IRD (P < 0.001) and NIRD (P = 0.07), compared with nondiabetics. TLR rates were comparable in NIRD and nondiabetics, but significantly higher in IRD (P = 0.04). No difference was observed in ST. Conclusion: The 1‐year results of the Genous stent in a real‐world population of diabetics show higher TVF rates in diabetics compared with nondiabetics, mainly driven by a higher mortality hazard. IRD is associated with a significant higher TLR hazard. Definite or probable ST in all diabetic patients was comparable with nondiabetics. (J Interven Cardiol 2011;24:285–294) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Twelve‐month Outcomes After Coronary Stenting With the Genous™ Bio‐Engineered R Stent™ in Diabetic Patients from the e‐HEALING Registry

Download PDF
10 pages

Loading next page...
 
/lp/wiley/twelve-month-outcomes-after-coronary-stenting-with-the-genous-bio-WRM8xTgLre

References (27)

Publisher
Wiley
Copyright
©2011, Wiley Periodicals, Inc.
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2010.00624.x
pmid
21281358
Publisher site
See Article on Publisher Site

Abstract

Objectives: We compared 12‐month outcomes, regarding ischemic events, repeat intervention, and ST, between diabetic and nondiabetic patients treated with the Genous™ EPC capturing R stent™ during routine nonurgent percutaneous coronary intervention (PCI) using data from the multicenter, prospective worldwide e‐HEALING registry. Background: Diabetic patients have an increased risk for restenosis and stent thrombosis (ST). Methods: In the 4,996 patient e‐HEALING registry, 273 were insulin requiring diabetics (IRD), 963 were non‐IRD (NIRD), and 3,703 were nondiabetics. The 12‐month primary outcome was target vessel failure (TVF), defined as target vessel–related cardiac death or myocardial infarction (MI) and target vessel revascularization. Secondary outcomes were the composite of cardiac death, MI or target lesion revascularization (TLR), and individual outcomes including ST. Cumulative event rates were estimated with the Kaplan–Meier method and compared with a log‐rank test. Results: TVF rates were respectively 13.4% in IRD, 9.0% in NIRD, and 7.9% in nondiabetics (P < 0.01). This was mainly driven by a higher mortality hazard in IRD (P < 0.001) and NIRD (P = 0.07), compared with nondiabetics. TLR rates were comparable in NIRD and nondiabetics, but significantly higher in IRD (P = 0.04). No difference was observed in ST. Conclusion: The 1‐year results of the Genous stent in a real‐world population of diabetics show higher TVF rates in diabetics compared with nondiabetics, mainly driven by a higher mortality hazard. IRD is associated with a significant higher TLR hazard. Definite or probable ST in all diabetic patients was comparable with nondiabetics. (J Interven Cardiol 2011;24:285–294)

Journal

Journal of Interventional Cardiology – Wiley

Published: Aug 1, 2011

There are no references for this article.